My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 11 714 / DOI: 10.3332/ecancer.2017.714

Review

Gastric cancer and related epigenetic alterations

Gastric cancer, a malignant and highly proliferative condition, has significantly affected a large population around the globe and is known to be caused by various factors including genetic, epigenetic, and environmental influences. Though the global trend of these cancers is declining, an increase in its frequency is still a threat because of changing lifestyles and dietary habits. However, genetic and epigenetic alterations related to gastric cancers also have an equivalent contribution towards carcinogenic development. DNA methylation is one of the major forms of epigenetic modification which plays a significant role in gastric carcinogenesis. Methylation leads to inactivation of some of the most important genes like DNA repair genes, cell cycle regulators, apoptotic genes, transcriptional regulators, and signalling pathway regulators; which subsequently cause uncontrolled proliferation of cells. Mutations in these genes can be used as suitable prognostic markers for early diagnosis of the disease, since late diagnosis of gastric cancers has a huge negative impact on overall patient survival. In this review, we focus on the important epigenetic mutations that contribute to the development of gastric cancer and the molecular pathogenesis underlying each of them. Methylation, acetylation, and histone modifications play an integral role in the onset of genomic instability, one of the many contributory factors to gastric cancer. This article also covers the constraints of incomplete knowledge of epigenetic factors influencing gastric cancer, thus throwing light on our understanding of the disease.

Keywords: gastric cancer, epigenetics, histone modification, methylation, microsatellite instability

Loading Article Metrics ... Please wait

Related articles

Conference Report: Highlights from the first ecancer–Liga Colombiana contra el Cancer conference, 17–18 November 2016, Bogota, Colombia

Abstract | Full Article | PDF | Spanish Published: 28 Mar 2017 / DOI: 10.3332/ecancer.2017.730

Conference Report: Highlights from the ecancer Future Horizons in Lung Cancer conference, 1–2 September 2016: Focusing on the future of treatment for NSCLC and SCLC

Abstract | Full Article | PDF Published: 23 Mar 2017 / DOI: 10.3332/ecancer.2017.729

Conference Report: Highlights from the 36th European Society of Surgical Oncology Congress (ESSO 36), 14–16 September 2016, Kracow, Poland: optimising European cancer surgery

Abstract | Full Article | PDF Published: 23 Mar 2017 / DOI: 10.3332/ecancer.2017.728

Review: Dual role of inflammatory mediators in cancer

Abstract | Full Article | PDF Published: 23 Feb 2017 / DOI: 10.3332/ecancer.2017.721

Research: Circulating and tissue biomarkers in early-stage non-small cell lung cancer

Abstract | Full Article | PDF Published: 31 Jan 2017 / DOI: 10.3332/ecancer.2017.717



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence